AIM
ABCL icon

Arcadia Investment Management’s AbCellera Biologics ABCL Stock Holding History

Arcadia Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$26K – 305
2024
Q3 		$26K Buy
+10,000
New +$27.7K ﹤0.01% 201

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arcadia Investment Management's ABCL Position: Q4 2024 in Review

Arcadia Investment Management sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 10,000 shares — an estimated $26K sold.

Arcadia Investment Management first reported a position in ABCL in Q3 2024 and held it in 1 quarter. The position peaked at $26K in Q3 2024. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Arcadia Investment Management reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Arcadia Investment Management sold 10,000 AbCellera Biologics shares in Q4 2024, an estimated $26K.
  • Arcadia Investment Management first reported a position in AbCellera Biologics in Q3 2024 and held it in 1 quarter.
  • Arcadia Investment Management's AbCellera Biologics position peaked at $26K in Q3 2024.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Arcadia Investment Management's 13F filing for Q4 2024, filed 3 Feb 2025.